Saudi Central Bank Grows Position in Humana Inc. $HUM

Key Points

• Saudi Central Bank increased its Humana stake by 89.3% in the second quarter, bringing its holdings to 8,404 shares worth approximately $3.34 million. Institutional investors collectively own 92.38% of Humana.
• Humana exceeded quarterly earnings expectations, reporting $7.61 in EPS versus the $7.27 consensus, while revenue rose 26.2% year over year to $40.89 billion.
• The company declared a quarterly dividend of $0.885 per share, equivalent to a 0.9% yield. Analysts maintain a consensus “Hold” rating with an average price target of $403.91, near the stock’s $400.70 opening price.

Saudi Central Bank boosted its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 89.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,404 shares of the insurance provider's stock after acquiring an additional 3,965 shares during the period. Saudi Central Bank's holdings in Humana were worth $3,338,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Revolve Wealth Partners LLC purchased a new stake in shares of Humana in the fourth quarter worth about $202,000. Woodline Partners LP increased its stake in Humana by 460.0% in the 1st quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider's stock worth $2,697,000 after acquiring an additional 8,372 shares during the last quarter. Sivia Capital Partners LLC increased its stake in Humana by 53.7% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider's stock worth $316,000 after acquiring an additional 452 shares during the last quarter. Cresset Asset Management LLC raised its holdings in shares of Humana by 10.3% during the 2nd quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider's stock worth $581,000 after acquiring an additional 222 shares in the last quarter. Finally, WINTON GROUP Ltd boosted its position in shares of Humana by 58.5% during the 2nd quarter. WINTON GROUP Ltd now owns 2,381 shares of the insurance provider's stock valued at $582,000 after acquiring an additional 879 shares during the last quarter. Institutional investors own 92.38% of the company's stock.

Humana Stock Down 0.2%

Shares of NYSE:HUM opened at $400.70 on Tuesday. The firm has a market capitalization of $48.12 billion, a PE ratio of 37.91, a price-to-earnings-growth ratio of 2.63 and a beta of 0.74. The business has a 50 day simple moving average of $388.67 and a two-hundred day simple moving average of $298.31. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $428.88. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, topping the consensus estimate of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The firm had revenue of $40.89 billion for the quarter, compared to the consensus estimate of $40.58 billion. During the same period in the prior year, the business posted $6.27 earnings per share. The company's revenue for the quarter was up 26.2% on a year-over-year basis. On average, equities analysts predict that Humana Inc. will post 9 EPS for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 27th. Stockholders of record on Friday, October 30th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, October 30th. Humana's dividend payout ratio (DPR) is 33.49%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Robert W. Baird set a $390.00 price target on shares of Humana in a research note on Thursday, July 30th. Truist Financial upped their target price on shares of Humana from $320.00 to $415.00 and gave the company a "hold" rating in a research report on Tuesday, July 14th. Weiss Ratings raised shares of Humana from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, August 14th. Barclays boosted their price objective on Humana from $344.00 to $407.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Finally, Raymond James Financial downgraded Humana from an "outperform" rating to a "market perform" rating in a research report on Thursday, July 30th. Fourteen investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Humana currently has an average rating of "Hold" and a consensus price target of $403.91.

Humana Profile

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.